---
schema_version: "secwatch.filing_event.v1"
accession: "0001501697-25-000041"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:15:32.631934+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma Q3 net loss $29.8M ($0.69/sh); cash runway to end 2028 after $240.3M financing

## Summary
- Q3 net product sales XOLREMDI $1.6M vs $0.6M YoY; net loss $0.69/sh vs $5.48/sh in Q3 2024.
- Raised $240.3M gross via public offering and upsized private placement; cash runway extended to end of 2028.
- 50% workforce reduction yields ~$13M annualized cost savings; focus on Phase 3 4WARD chronic neutropenia trial.
- Enrollment target for 4WARD increased to 176 patients; expected completion Q3 2026; sNDA potential in chronic neutropenia.
- Deprioritized XOLREMDI commercialization for WHIM syndrome; John Volpone promoted to COO.

## SEC filing metadata
- accession: 0001501697-25-000041
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/0001501697-25-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/xfor-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001501697-25-000041
- JSON: https://secwatch.observer/filing/0001501697-25-000041.json
- Plain text: https://secwatch.observer/filing/0001501697-25-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.